tetano
Editor, Senior Moderator
BMC Infect Dis. 2016 Jul 8;16:325. doi: 10.1186/s12879-016-1589-9.
[h=1]Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment.[/h] Li Z[SUP]1[/SUP], Li R[SUP]1[/SUP], Li J[SUP]1[/SUP], Xie H[SUP]1[/SUP], Hao Y[SUP]1[/SUP], Du Q[SUP]1[/SUP], Chen T[SUP]1[/SUP], Li Y[SUP]1[/SUP], Chen R[SUP]2[/SUP], Yang Z[SUP]3,[/SUP][SUP]4[/SUP], Zhong N[SUP]1,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug shows an inconclusive efficacy if treatment is delayed in clinical. Thus we evaluated the efficacy of delayed treatment of China-made Peramivir in a mouse model.
[h=4]METHODS:[/h] The mouse model of influenza infection was made and Peramivir was administered intravenously for 5 days following infection, and weight loss, lung index, viral shedding and survival rates were monitored.
[h=4]RESULTS:[/h] Peramivir (60 mg/kg ? d, repeated intravenous injections, quaque die (QD) ? 5 days) enhanced survival rate and suppressed weight loss when treatment was initiated 24, 36, 48, or even 60 h post-infection (p.i.) (p < 0.01), compared with the virus-untreated group, and efficacy was abolished at 72 h p.i.. However the efficacy of delayed treatment was dose dependent, with the highest dose (90 mg/kg ? d) even showing efficacy at 72 h p.i.. Furthermore, Peramivir (60 mg/kg ? d, repeated intravenous injections, QD ? 5 days) also reduced the lung virus titer 24 and 36 h p.i. on day 5, and even at 48 and 60 h p.i. on day 7 after infection, and the lung index was also improved. What is interesting that the concentration of the drug was maintained in blood after infected.
[h=4]CONCLUSIONS:[/h] Delayed treatment with China-made Peramivir can reduce the severity of influenza disease, accelerate viral clearance and enhance the survival rate. This drug therefore shows good efficacy and is a promising candidate to control the influenza epidemic in China.
[h=4]KEYWORDS:[/h] Delayed treatment; Lung index; Lung virus titer; Peramivir; Survival rate
PMID: 27392915 DOI: 10.1186/s12879-016-1589-9
[PubMed - in process] Free full text
[h=1]Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment.[/h] Li Z[SUP]1[/SUP], Li R[SUP]1[/SUP], Li J[SUP]1[/SUP], Xie H[SUP]1[/SUP], Hao Y[SUP]1[/SUP], Du Q[SUP]1[/SUP], Chen T[SUP]1[/SUP], Li Y[SUP]1[/SUP], Chen R[SUP]2[/SUP], Yang Z[SUP]3,[/SUP][SUP]4[/SUP], Zhong N[SUP]1,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug shows an inconclusive efficacy if treatment is delayed in clinical. Thus we evaluated the efficacy of delayed treatment of China-made Peramivir in a mouse model.
[h=4]METHODS:[/h] The mouse model of influenza infection was made and Peramivir was administered intravenously for 5 days following infection, and weight loss, lung index, viral shedding and survival rates were monitored.
[h=4]RESULTS:[/h] Peramivir (60 mg/kg ? d, repeated intravenous injections, quaque die (QD) ? 5 days) enhanced survival rate and suppressed weight loss when treatment was initiated 24, 36, 48, or even 60 h post-infection (p.i.) (p < 0.01), compared with the virus-untreated group, and efficacy was abolished at 72 h p.i.. However the efficacy of delayed treatment was dose dependent, with the highest dose (90 mg/kg ? d) even showing efficacy at 72 h p.i.. Furthermore, Peramivir (60 mg/kg ? d, repeated intravenous injections, QD ? 5 days) also reduced the lung virus titer 24 and 36 h p.i. on day 5, and even at 48 and 60 h p.i. on day 7 after infection, and the lung index was also improved. What is interesting that the concentration of the drug was maintained in blood after infected.
[h=4]CONCLUSIONS:[/h] Delayed treatment with China-made Peramivir can reduce the severity of influenza disease, accelerate viral clearance and enhance the survival rate. This drug therefore shows good efficacy and is a promising candidate to control the influenza epidemic in China.
[h=4]KEYWORDS:[/h] Delayed treatment; Lung index; Lung virus titer; Peramivir; Survival rate
PMID: 27392915 DOI: 10.1186/s12879-016-1589-9
[PubMed - in process] Free full text